TET2, a tumor suppressor in hematological disorders

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 2, 2012, Pages 173-177

  Mercher, Thomas ^a,b,c   Quivoron, Cyril ^a,b,c   Couronné, Lucile ^a,b,c   Bastard, Christian ^d   Vainchenker, William ^b,c,e   Bernard, Olivier A ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e Universite Paris Sud   (France)

Author keywords

Epigenetics; Hematology; Mouse models; Oncology; Tumor suppressor

Indexed keywords

5 CARBOXYLCYTOSINE; 5 FORMYLCYTOSINE; 5 HYDROXYMETHYLCYTOSINE; CYTOSINE DERIVATIVE; DNA; METHYLCYTOSINE; PROTEIN TET2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; DNA METHYLATION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MALIGNANT TRANSFORMATION; MOLECULAR PATHOLOGY; MULTIGENE FAMILY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; TET2 GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; DISEASE MODELS, ANIMAL; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENOMICS; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HUMANS; PROTO-ONCOGENE PROTEINS;

EID: 84856069777     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.12.002     Document Type: Review

References (57)

1. Berger A.H., Pandolfi P.P. Haplo-insufficiency: a driving force in cancer. J. Pathol. 2011, 223:137-146.
2. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
3. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res. 2002, 62:4075-4080.
4. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Masse A., Kosmider O., Le Couedic J.P., Robert F., Alberdi A., Lecluse Y., Plo I., Dreyfus F.J., Marzac C., Casadevall N., Lacombe C., Romana S.P., Dessen P., Soulier J., Viguie F., Fontenay M., Vainchenker W., Bernard O.A. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 2009, 360:2289-2301.
5. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., Stevens-Linders E., van Hoogen P., van Kessel A.G., Raymakers R.A., Kamping E.J., Verhoef G.E., Verburgh E., Hagemeijer A., Vandenberghe P., de Witte T., van der Reijden B.A., Jansen J.H. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009, 41:838-842.
6. Tefferi A., Levine R.L., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., Finke C.M., Mullally A., Li C.Y., Pardanani A., Gilliland D.G. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23:900-904.
7. Tefferi A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., Patnaik M.M., Hanson C.A., Pardanani A., Gilliland D.G., Levine R.L. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345.
8. Tefferi A., Pardanani A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., Gangat N., Finke C.M., Schwager S., Mullally A., Li C.Y., Hanson C.A., Mesa R., Bernard O., Delhommeau F., Vainchenker W., Gilliland D.G., Levine R.L. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23:905-911.
9. Jankowska A.M., Szpurka H., Tiu R.V., Makishima H., Afable M., Huh J., O'Keefe C.L., Ganetzky R., McDevitt M.A., Maciejewski J.P. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-6410.
10. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., Malinge S., Yao J., Kilpivaara O., Bhat R., Huberman K., Thomas S., Dolgalev I., Heguy A., Paietta E., Le Beau M.M., Beran M., Tallman M.S., Ebert B.L., Kantarjian H.M., Stone R.M., Gilliland D.G., Crispino J.D., Levine R.L. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
11. Kosmider O., Gelsi-Boyer V., Ciudad M., Racoeur C., Jooste V., Vey N., Quesnel B., Fenaux P., Bastie J.N., Beyne-Rauzy O., Stamatoulas A., Dreyfus F., Ifrah N., de Botton S., Vainchenker W., Bernard O.A., Birnbaum D., Fontenay M., Solary E. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009, 94:1676-1681.
12. Levine R.L., Carroll M. A common genetic mechanism in malignant bone marrow diseases. N. Engl. J. Med. 2009, 360:2355-2357.
13. Couronne L., Lippert E., Andrieux J., Kosmider O., Radford-Weiss I., Penther D., Dastugue N., Mugneret F., Lafage M., Gachard N., Nadal N., Bernard O.A., Nguyen-Khac F. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010, 24:201-203.
14. Kiladjian J.J., Masse A., Cassinat B., Mokrani H., Teyssandier I., le Couedic J.P., Cambier N., Almire C., Pronier E., Casadevall N., Vainchenker W., Chomienne C., Delhommeau F. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 2010, 24:1519-1523.
15. Vainchenker W., Delhommeau F., Constantinescu S.N., Bernard O.A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011, 118:1723-1735.
16. Pronier E., Quivoron C., Bernard O.A., Villeval J.L. JAK2V(1)F/TET2 mutations: does the order matter?. Haematologica 2011, 96:638-640.
17. Swierczek S.I., Yoon D., Bellanne-Chantelot C., Kim S.J., Saint-Martin C., Delhommeau F., Najman A., Prchal J.T. Extent of hematopoietic involvement by TET2 mutations in JAK2V(1)F polycythemia vera. Haematologica 2011, 96:775-778.
18. Saint-Martin C., Leroy G., Delhommeau F., Panelatti G., Dupont S., James C., Plo I., Bordessoule D., Chomienne C., Delannoy A., Devidas A., Gardembas-Pain M., Isnard F., Plumelle Y., Bernard O., Vainchenker W., Najman A., Bellanne-Chantelot C. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009, 114:1628-1632.
19. Schaub F.X., Looser R., Li S., Hao-Shen H., Lehmann T., Tichelli A., Skoda R.C. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010, 115:2003-2007.
20. Beer P.A., Delhommeau F., LeCouedic J.P., Dawson M.A., Chen E., Bareford D., Kusec R., McMullin M.F., Harrison C.N., Vannucchi A.M., Vainchenker W., Green A.R. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115:2891-2900.
21. Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., Della-Valle V., Picard F., Viguie F., Quesnel B., Beyne-Rauzy O., Solary E., Vey N., Hunault-Berger M., Fenaux P., Mansat-De Mas V., Delabesse E., Guardiola P., Lacombe C., Vainchenker W., Preudhomme C., Dreyfus F., Bernard O.A., Birnbaum D., Fontenay M. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285-3291.
22. Nibourel O., Kosmider O., Cheok M., Boissel N., Renneville A., Philippe N., Dombret H., Dreyfus F., Quesnel B., Geffroy S., Quentin S., Roche-Lestienne C., Cayuela J.M., Roumier C., Fenaux P., Vainchenker W., Bernard O.A., Soulier J., Fontenay M., Preudhomme C. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010, 116:1132-1135.
23. Kosmider O., Delabesse E., de Mas V.M., Cornillet-Lefebvre P., Blanchet O., Delmer A., Recher C., Raynaud S., Bouscary D., Viguie F., Lacombe C., Bernard O.A., Ifrah N., Dreyfus F., Fontenay M. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica 2011, 96:1059-1063.
24. Nguyen-Khac F., Lesty C., Eclache V., Couronne L., Kosmider O., Andrieux J., Collonge-Rame M.A., Penther D., Lafage M., Bilhou-Nabera C., Chapiro E., Mozziconacci M.J., Mugneret F., Gachard N., Nadal N., Lippert E., Struski S., Dastugue N., Cabrol C., Bernard O.A. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer 2010, 49:919-927.
25. Chou W.C., Chou S.C., Liu C.Y., Chen C.Y., Hou H.A., Kuo Y.Y., Lee M.C., Ko B.S., Tang J.L., Yao M., Tsay W., Wu S.J., Huang S.Y., Hsu S.C., Chen Y.C., Chang Y.C., Kuo K.T., Lee F.Y., Liu M.C., Liu C.W., Tseng M.H., Huang C.F., Tien H.F. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011, 118:3803-3810.
26. Metzeler K.H., Maharry K., Radmacher M.D., Mrozek K., Margeson D., Becker H., Curfman J., Holland K.B., Schwind S., Whitman S.P., Wu Y.Z., Blum W., Powell B.L., Carter T.H., Wetzler M., Moore J.O., Kolitz J.E., Baer M.R., Carroll A.J., Larson R.A., Caligiuri M.A., Marcucci G., Bloomfield C.D. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2011, 29:1373-1381.
27. Quivoron C., Couronne L., Della Valle V., Lopez C.K., Plo I., Wagner-Ballon O., Do Cruzeiro M., Delhommeau F., Arnulf B., Stern M.H., Godley L., Opolon P., Tilly H., Solary E., Duffourd Y., Dessen P., Merle-Beral H., Nguyen-Khac F., Fontenay M., Vainchenker W., Bastard C., Mercher T., Bernard O.A. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20:25-38.
28. Moran-Crusio K., Reavie L., Shih A., Abdel-Wahab O., Ndiaye-Lobry D., Lobry C., Figueroa M.E., Vasanthakumar A., Patel J., Zhao X., Perna F., Pandey S., Madzo J., Song C., Dai Q., He C., Ibrahim S., Beran M., Zavadil J., Nimer S.D., Melnick A., Godley L.A., Aifantis I., Levine R.L. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
29. Li Z., Cai X., Cai C., Wang J., Zhang W., Petersen B.E., Yang F.C., Xu M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
30. Ko M., Bandukwala H.S., An J., Lamperti E.D., Thompson E.C., Hastie R., Tsangaratou A., Rajewsky K., Koralov S.B., Rao A. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14566-14571.
31. Viguie F., Aboura A., Bouscary D., Ramond S., Delmer A., Tachdjian G., Marie J.P., Casadevall N. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?. Leukemia 2005, 19:1411-1415.
32. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M., Jackman S., Krzywinski M., Scott D.W., Trinh D.L., Tamura-Wells J., Li S., Firme M.R., Rogic S., Griffith M., Chan S., Yakovenko O., Meyer I.M., Zhao E.Y., Smailus D., Moksa M., Chittaranjan S., Rimsza L., Brooks-Wilson A., Spinelli J.J., Ben-Neriah S., Meissner B., Woolcock B., Boyle M., McDonald H., Tam A., Zhao Y., Delaney A., Zeng T., Tse K., Butterfield Y., Birol I., Holt R., Schein J., Horsman D.E., Moore R., Jones S.J., Connors J.M., Hirst M., Gascoyne R.D., Marra M.A. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
33. Kikushige Y., Ishikawa F., Miyamoto T., Shima T., Urata S., Yoshimoto G., Mori Y., Iino T., Yamauchi T., Eto T., Niiro H., Iwasaki H., Takenaka K., Akashi K. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011, 20:246-259.
34. Cimmino L. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011, 9.
35. Matarese F., Carrillo de Santa Pau E., Stunnenberg H.G. 5-hydroxymethylcytosine: a new kid on the epigenetic block?. Mol Syst Biol 2011, 7:562.
36. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 2011, 10.
37. Williams K., Christensen J., Helin K. DNA methylation: TET proteins-guardians of CpG islands?. EMBO Rep 2011, 13:28-35.
38. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
39. Koh K.P., Yabuuchi A., Rao S., Huang Y., Cunniff K., Nardone J., Laiho A., Tahiliani M., Sommer C.A., Mostoslavsky G., Lahesmaa R., Orkin S.H., Rodig S.J., Daley G.Q., Rao A. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8:200-213.
40. He Y.F., Li B.Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., Sun Y., Li X., Dai Q., Song C.X., Zhang K., He C., Xu G.L. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
41. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
42. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
43. Penn N.W., Suwalski R., O'Riley C., Bojanowski K., Yura R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem. J. 1972, 126:781-790.
44. Kriaucionis S., Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324:929-930.
45. Cortellino S., Xu J., Sannai M., Moore R., Caretti E., Cigliano A., Le Coz M., Devarajan K., Wessels A., Soprano D., Abramowitz L.K., Bartolomei M.S., Rambow F., Bassi M.R., Bruno T., Fanciulli M., Renner C., Klein-Szanto A.J., Matsumoto Y., Kobi D., Davidson I., Alberti C., Larue L., Bellacosa A. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146:67-79.
46. Valinluck V., Sowers L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res. 2007, 67:946-950.
47. Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A., Rappsilber J., Helin K. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011, 473:343-348.
48. Dawlaty M.M., Ganz K., Powell B.E., Hu Y.C., Markoulaki S., Cheng A.W., Gao Q., Kim J., Choi S.W., Page D.C., Jaenisch R. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011, 9:166-175.
49. Wossidlo M., Nakamura T., Lepikhov K., Marques C.J., Zakhartchenko V., Boiani M., Arand J., Nakano T., Reik W., Walter J. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat. Commun. 2011, 2:241.
50. Gu T.-P., Guo F., Yang H., Wu H.-P., Xu G.-F., Liu W., Xie Z.-G., Shi L., He X., Jin S.-g., Iqbal K., Shi Y.G., Deng Z., Szabo P.E., Pfeifer G.P., Li J., Xu G.-L. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011, 477:606-610.
51. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., An J., Lamperti E.D., Koh K.P., Ganetzky R., Liu X.S., Aravind L., Agarwal S., Maciejewski J.P., Rao A. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
52. Pronier E., Almire C., Mokrani H., Vasanthakumar A., Simon A., da Costa Reis Monte Mor B., Masse A., Le Couedic J.P., Pendino F., Carbonne B., Larghero J., Ravanat J.L., Casadevall N., Bernard O.A., Droin N., Solary E., Godley L.A., Vainchenker W., Plo I., Delhommeau F. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118:2551-2555.
53. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., Fulton L.A., Locke D.P., Magrini V.J., Abbott R.M., Vickery T.L., Reed J.S., Robinson J.S., Wylie T., Smith S.M., Carmichael L., Eldred J.M., Harris C.C., Walker J., Peck J.B., Du F., Dukes A.F., Sanderson G.E., Brummett A.M., Clark E., McMichael J.F., Meyer R.J., Schindler J.K., Pohl C.S., Wallis J.W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M.E., Ivy J.V., Kalicki J., Elliott G., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M.A., Baty J., Heath S., Shannon W.D., Nagarajan R., Link D.C., Walter M.J., Graubert T.A., DiPersio J.F., Wilson R.K., Ley T.J. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361:1058-1066.
54. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z., Wolniak K., Peeters J.K., Liu W., Choe S.E., Fantin V.R., Paietta E., Lowenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J., Thompson C.B., Levine R.L., Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
55. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
56. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Xiao M.T., Liu L.X., Jiang W.Q., Liu J., Zhang J.Y., Wang B., Frye S., Zhang Y., Xu Y.H., Lei Q.Y., Guan K.L., Zhao S.M., Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
57. Loenarz C., Schofield C.J. Oxygenase catalyzed 5-methylcytosine hydroxylation. Chem. Biol. 2009, 16:580-583.